Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas
暂无分享,去创建一个
[1] J. Price. Metastasis from human breast cancer cell lines , 2005, Breast Cancer Research and Treatment.
[2] P. Heikkilä,et al. Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. , 2003, Cancer research.
[3] H. Sewell,et al. The production and characterisation of a chimaeric human IgE antibody, recognising the major mite allergen Der p 1, and its chimaeric human IgG1 anti-idiotype , 2002, Molecular pathology : MP.
[4] D. Larsimont,et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] D. Larsimont,et al. Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. , 2002, Journal of clinical pathology.
[6] R. Xu,et al. Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material , 2002, Modern Pathology.
[7] A. Thor. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? , 2001, Journal of the National Cancer Institute.
[8] H. Moch,et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.
[9] J. Isola,et al. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. , 2001, Cancer research.
[10] D. Chan,et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. , 2001, Anticancer research.
[11] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[12] L. Krogerus,et al. HER-2/neu oncogene expression in advanced breast cancer. , 2001, Cancer detection and prevention.
[13] A. Dnistrian,et al. Monitoring Therapy by Serum HER-2/Neu , 2000, The International journal of biological markers.
[14] M. Bui,et al. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. , 2000, Annals of clinical and laboratory science.
[15] C. Shimizu,et al. c‐erbB‐2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues , 2000, Journal of surgical oncology.
[16] K. Kinzler,et al. Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.
[17] J. Fletcher,et al. HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.
[18] S. Hirohashi,et al. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c‐erbB‐2 expression patterns in both the non‐invasive and invasive portions , 1998, Pathology international.
[19] T. Shankey,et al. Common patterns of genetic evolution in human solid tumors. , 1997, Cytometry.
[20] R. Zeillinger,et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. , 1997, Oncology.
[21] D. Slamon,et al. HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer , 1997, Stem cells.
[22] T. Singleton,et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.
[23] L. Demers,et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Pinkel,et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Price. The biology of metastatic breast cancer , 1990, Cancer.
[26] S. Naber,et al. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. , 1990, American journal of clinical pathology.
[27] N. Lemoine,et al. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. , 1990, Oncogene.
[28] D. Altman,et al. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.
[29] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.